| Dr William S Lim, MD | |
|
5005 N Piedras St, Wbamc Ophthalmology Clinic, 2178, El Paso, TX 79920-5001 | |
| (915) 569-4432 | |
| (915) 569-1233 |
| Full Name | Dr William S Lim |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 25 Years |
| Location | 5005 N Piedras St, El Paso, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023107380 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | A99969 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has agreed to purchase the remaining interest of its joint venture in Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and related assets from Danaher Corporation. Danaher acquired this joint venture stake and these assets as part of its acquisition of MDS Inc.'s Analytical Technologies business.
Genomas(R), a biomedical company advancing DNA-Guided medicine, today announced the award of a 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling $1.4 Million. The grant, entitled MRI DNA Biomarkers for Neuropsychiatric Disease, was awarded by the National Institute of Mental Health.
dbMotion, an innovative provider of connected healthcare solutions, and Matrix Knowledge Group, a leader in information management services, announced a partnership today to jointly market and deploy solutions throughout the United Kingdom.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
National Cancer Institute (NCI) scientists have discovered how human T-cell leukemia virus type 1 (HTLV-1), which infects about 20 million people worldwide, evades being held in check by one of the body's natural defense mechanisms.
› Verified 7 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has agreed to purchase the remaining interest of its joint venture in Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and related assets from Danaher Corporation. Danaher acquired this joint venture stake and these assets as part of its acquisition of MDS Inc.'s Analytical Technologies business.
Genomas(R), a biomedical company advancing DNA-Guided medicine, today announced the award of a 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling $1.4 Million. The grant, entitled MRI DNA Biomarkers for Neuropsychiatric Disease, was awarded by the National Institute of Mental Health.
dbMotion, an innovative provider of connected healthcare solutions, and Matrix Knowledge Group, a leader in information management services, announced a partnership today to jointly market and deploy solutions throughout the United Kingdom.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
National Cancer Institute (NCI) scientists have discovered how human T-cell leukemia virus type 1 (HTLV-1), which infects about 20 million people worldwide, evades being held in check by one of the body's natural defense mechanisms.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William S Lim, MD 5005 N Piedras St, Wbamc Ophthalmology Clinic, 2178, El Paso, TX 79920-5001 Ph: (915) 569-4432 | Dr William S Lim, MD 5005 N Piedras St, Wbamc Ophthalmology Clinic, 2178, El Paso, TX 79920-5001 Ph: (915) 569-4432 |
News Archive
PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has agreed to purchase the remaining interest of its joint venture in Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and related assets from Danaher Corporation. Danaher acquired this joint venture stake and these assets as part of its acquisition of MDS Inc.'s Analytical Technologies business.
Genomas(R), a biomedical company advancing DNA-Guided medicine, today announced the award of a 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling $1.4 Million. The grant, entitled MRI DNA Biomarkers for Neuropsychiatric Disease, was awarded by the National Institute of Mental Health.
dbMotion, an innovative provider of connected healthcare solutions, and Matrix Knowledge Group, a leader in information management services, announced a partnership today to jointly market and deploy solutions throughout the United Kingdom.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV™ ODT (metoclopramide HCl) 5mg and 10mg orally disintegrating tablets. METOZOLV ODT is indicated for the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis and for the treatment of short-term therapy (4-12 weeks) for adults with symptomatic documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy1.
National Cancer Institute (NCI) scientists have discovered how human T-cell leukemia virus type 1 (HTLV-1), which infects about 20 million people worldwide, evades being held in check by one of the body's natural defense mechanisms.
› Verified 7 days ago
Dr. Daniel S. Washburn, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5005 N Piedras St, Wbamc, El Paso, TX 79920 Phone: 915-569-2107 Fax: 915-569-1233 | |
Dr. William Francis Davitt Iii, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 8815 Dyer St, Suite 130, El Paso, TX 79904 Phone: 915-757-3937 Fax: 915-757-3946 | |
James D Cole, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1400 Common Dr, El Paso, TX 79936 Phone: 915-595-4375 Fax: 915-575-4460 | |
Girvar Singh, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 5001 N Piedras St, El Paso, TX 79930 Phone: 915-564-6116 Fax: 915-564-7940 | |
Dr. Susan Lynne Parks, Ophthalmology Medicare: Medicare Enrolled Practice Location: 5001 N. Piedras, El Paso, TX 79930 Phone: 915-564-6116 Fax: 915-564-7940 | |
Robert Mclemore Maddox, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 601 Sunland Park Dr, Building 2, El Paso, TX 79912 Phone: 915-881-8100 |